Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy-Reference-Cited by-同舟云学术

Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy

Published:2010-09-28 Issue:9 Volume:103 Page:1318-1324
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bernhard J,Dietrich D,Glimelius B,Hess V,Bodoky G,Scheithauer W,Herrmann R

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6605929.pdf

Reference24 articles.

1. Bernhard J, Dietrich D, Scheithauer W, Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Kohne C-H, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Herrmann R (2008) Clinical benefit and quality of life in patients with advanced pancreatic cancer receiving gemcitabine plus capecitabine versus gemcitabine alone: a randomized Multicenter phase III clinical trial--SAKK 44/00-CECOG/PAN. 1.3.001. J Clin Oncol 26: 3695–3701

2. Bernhard J, Hurny C, Maibach R, Herrmann R, Laffer U (1999) Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 10: 775–782

3. Bernhard J, Sullivan M, Hurny C, Coates AS, Rudenstam CM (2001) Clinical relevance of single item quality of life indicators in cancer clinical trials. Br J Cancer 84: 1156–1165

4. Borner MM, Bernhard J, Dietrich D, Popescu R, Wernli M, Saletti P, Rauch D, Herrmann R, Koeberle D, Honegger H, Brauchli P, Lanz D, Roth AD (2005) A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol 16: 282–288

5. Butow P, Coates A, Dunn S, Bernhard J, Hurny C (1991) On the receiving end. IV: validation of quality of life indicators. Ann Oncol 2: 597–603

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic impact of the ratio of preoperative CA19-9 to liver enzyme levels in pancreatic cancer patients with jaundice (predictability of combined CA19-9/AST and CA19-9/γ-GGT for jaundiced PDAC patients);Pancreatology;2021-09

2. Patient Reported Outcome Measures of Health-Related Quality of Life and Asthenia after Thyroidectomy;Journal of Surgical Research;2021-08

3. Improving quality of life in pancreatic cancer patients following high-intensity focused ultrasound (HIFU) in two European centers;European Radiology;2021-01-23

4. An assessment of the use of patient reported outcome measurements (PROMs) in cancers of the pelvic abdominal cavity: identifying oncologic benefit and an evidence-practice gap in routine clinical practice;Health and Quality of Life Outcomes;2021-01-15

5. The Role of CA 19-9 in Pancreatic Adenocarcinoma;Textbook of Pancreatic Cancer;2021